AI Article Synopsis

  • The study assessed the safety of at-home ocrelizumab infusions for multiple sclerosis patients, focusing on infusion-related reactions (IRRs) and patient satisfaction.* -
  • It involved 99 participants who received a 600-mg infusion, with a noted IRR incidence rate of 25.3%, while most adverse events reported were mild or moderate.* -
  • Patients expressed higher satisfaction and confidence in the home infusion process compared to previous experiences at infusion centers, highlighting the feasibility of this approach.*

Article Abstract

Objective: This study aimed to evaluate safety (infusion-related reactions [IRRs]) and patient satisfaction (patient-reported outcomes [PROs]) for at-home ocrelizumab administration for patients with multiple sclerosis (MS).

Methods: This open-label study included adult patients with an MS diagnosis who had completed a ≥ 600-mg ocrelizumab dose, had a patient-determined disease steps score of 0 to 6 and had completed PROs. Eligible patients received a 600-mg ocrelizumab home-based infusion over 2 h, followed by 24-h and 2-week post-infusion follow-up calls. IRRs and adverse events (AEs) were documented during infusions and follow-up calls. PROs were completed before and 2 weeks post infusion.

Results: Overall, 99 of 100 expected patients were included (mean [SD] age, 42.3 [7.7] years; 72.7% female; 91.9% White). The mean (SD) infusion time was 2.5 (0.6) hours, and 75.8% of patients completed their ocrelizumab infusion between 2 to 2.5 h. The IRR incidence rate was 25.3% (95% CI: 16.7%, 33.8%)-similar to other shorter ocrelizumab infusion studies-and all AEs were mild/moderate. In total, 66.7% of patients experienced AEs, including itch, fatigue, and grogginess. Patients reported significantly increased satisfaction with the at-home infusion process and confidence in the care provided. Patients also reported a significant preference for at-home infusion compared with prior infusion center experiences.

Interpretation: IRRs and AEs occurred at acceptable rates during in-home infusions of ocrelizumab over a shorter infusion time. Patients reported increased confidence and comfort with the home infusion process. Findings from this study provide evidence of the safety and feasibility of home-based ocrelizumab infusion over a shorter infusion period.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109340PMC
http://dx.doi.org/10.1002/acn3.51745DOI Listing

Publication Analysis

Top Keywords

infusion
12
at-home infusion
12
patients reported
12
patients
9
multiple sclerosis
8
follow-up calls
8
infusion time
8
ocrelizumab infusion
8
reported increased
8
infusion process
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!